Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Further Reading from MarketBeat Media
Abbott Stock Crash: Rebound Could Be Coming FastBy Thomas Hughes. Article Published: 4/17/2026. 
Key Points
- Abbott Laboratories' stock price sell-off is overblown and unrealistic, providing an attractive opportunity in Q2.
- Institutions and analysts are accumulating this stock, indicating solid double-digit upside potential.
- Acquisitional woe hinders price action in April, but sets the market up for positive surprises and rebound later this year.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Abbott Laboratories' (NYSE: ABT) share price corrected roughly 45% peak to trough, bottoming in early Q2 2026 after becoming deeply oversold, according to market action. There were reasons for the sell-off, but its severity seems excessive given the company's underlying fundamentals. Mixed late-2025 results, cautious guidance and concerns around the acquisition strategy spooked the market. The key question is who has been doing the selling and who has been buying — and the ownership and analyst data tell a fairly clear story. ABT Stock Is Well-Supported by Sell-Side Interests
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itself - it's the infrastructure behind it.
One small-cap company supplies a mission-critical component to Musk's xAI Colossus site that can't be built around. While retail waits for a ticker that doesn't exist yet, early money is moving into this supplier at a fraction of its potential value. See the small-cap stock powering the SpaceX buildout today
MarketBeat data shows solid sell-side support for Abbott. Among the 21 analysts tracked, the consensus sits at a Moderate Buy with an 81% Buy-side bias and a steady price-target trend. Some price-target reductions followed the Q4 results, but those adjustments tracked consensus and a more constructive tone has since re-emerged. Barclays analyst Matt Miksic raised his target in early April, maintaining an Overweight rating and setting a $144 target. That level is roughly 7.5% above the consensus price target and about 40% above the stock’s critical support level. Institutional investors are also bullish, owning more than 75% of the float and net-accumulating for seven consecutive months. The only caveat is that early Q2 activity shows some distribution, though that could reverse quickly. In Q1 2026 institutional buying accelerated, reaching multiyear highs even as the share price declined — a sign institutions were taking advantage of the weakness. If that cohort continues to buy the post-fiscal-Q1 dip, Abbott's downside is likely limited, with a probable floor in the mid-$90s. Abbott Laboratories Market Hits Bottom in Q2The ABT stock price pulled back sharply after the Q1 release and could weaken further, but early trading suggests a bottoming process. The price gapped lower at the open and then traded in a tight range near critical support levels, which indicates steadier demand at these lows. Volume spiked alongside the dip, reaching long-term intraday highs that align with accumulation activity. 
Technical indicators reinforce the case for a rebound: oscillators show deeply oversold readings while the MACD is diverging, suggesting bears are losing control and bulls are gaining influence. A clear catalyst would help accelerate the recovery — one plausible trigger is visible success integrating Exact Sciences (maker of Cologuard) into Abbott’s diagnostics business, which would bolster the company’s position in the high-growth oncology diagnostics market. The main risk is that the stock remains stuck near current lows for several quarters, but even that scenario presents buying opportunities. Investors can use these support levels as tactical entry points to accumulate shares. Abbott Laboratories Falls Despite a Solid QuarterAbbott didn’t report a bad quarter, but it did confirm near-term impacts from the acquisition. Revenue grew 7.8% year over year, with comparable growth of 3.7%. Foreign exchange was a notable tailwind, contributing roughly 400 basis points; U.S. sales rose 2.5% while international sales grew more than 4.5%. By segment, Nutrition was the weakest, declining 7.7% due to volume and pricing pressures. Diagnostics grew only 2.5% but should accelerate with Exact Sciences in the portfolio. Established Pharmaceuticals and Medical Technology led the way, advancing 9.0% and 8.1%, respectively — a reminder of the benefits of Abbott’s diversified business mix. Margins disappointed somewhat, but not to the degree that justifies a near-50% sell-off. Adjusted earnings were roughly in line with expectations despite the top-line strength. The bottom line: earnings remain sufficient to support Abbott’s strong balance sheet and ongoing capital returns, and management’s guidance is constructive. Management Guides In-Line With ExpectationsLooking ahead, management expects sequential revenue acceleration and margin recovery, forecasting about 7% comparable growth at the midpoint and $5.48 in annual adjusted EPS — roughly a penny above consensus. Given Abbott’s track record with acquisitions and integrations, the likely outcome is execution that outperforms conservative expectations. In the meantime, Abbott’s dividend and share buybacks should continue. The dividend yields a historically high ~2.5% at mid-April prices, and Abbott’s dividend pedigree is strong: the company is both a Dividend Aristocrat and a Dividend King, having raised its payout for more than 50 consecutive years. |
0 Response to "We're excited to have you on board"
Post a Comment